Gimeno, Juan ROlivotto, IacopoRodríguez, Ana IsabelHo, Carolyn YFernández, AdriánQuiroga, AlejandroEspinosa, Mari AngelesGómez-González, CristinaRobledo, MaríaTojal-Sierra, LucasDay, Sharlene MOwens, AnjaliBarriales-Villa, RobertoLarrañaga, Jose MaríaRodríguez-Palomares, JoseGonzález-Del-Hoyo, MaribelPiqueras-Flores, JesúsReza, NosheenChumakova, OlgaAshley, Euan AParikh, VictoriaWheeler, MatthewJacoby, DanielPereira, Alexandre CSaberi, SaraHelms, Adam SVillacorta, EduardoGallego-Delgado, Maríade Castro, DanielDomínguez, FernandoRipoll-Vera, TomásZorio-Grima, EstherSánchez-Martínez, José CarlosGarcía-Álvarez, AnaArbelo, ElenaMogollón, María VictoriaFuentes-Cañamero, María EugeniaGrande, EliasPeña, CarlosMonserrat, LorenzoLakdawala, Neal K2023-12-202023-12-202022-08ESC Heart Fail. 2022 Aug;9(4):2189-2198.http://hdl.handle.net/20.500.12105/16855AIMS To describe the natural history of SARS-CoV-2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events. METHODS AND RESULTS Three hundred and five patients [age 56.6 ± 16.9 years old, 191 (62.6%) male patients] with HCM and SARS-Cov-2 infection were enrolled. The control group consisted of 91 131 infected individuals. Endpoints were (i) SARS-CoV-2 related mortality and (ii) severe clinical course [death or intensive care unit (ICU) admission]. New onset of atrial fibrillation, ventricular arrhythmias, shock, stroke, and cardiac arrest were also recorded. Sixty-nine (22.9%) HCM patients were hospitalized for non-ICU level care, and 21 (7.0%) required ICU care. Seventeen (5.6%) died: eight (2.6%) of respiratory failure, four (1.3%) of heart failure, two (0.7%) suddenly, and three (1.0%) due to other SARS-CoV-2-related complications. Covariates associated with mortality in the multivariable were age {odds ratio (OR) per 10 year increase 2.25 [95% confidence interval (CI): 1.12-4.51], P = 0.0229}, baseline New York Heart Association class [OR per one-unit increase 4.01 (95%CI: 1.75-9.20), P = 0.0011], presence of left ventricular outflow tract obstruction [OR 5.59 (95%CI: 1.16-26.92), P = 0.0317], and left ventricular systolic impairment [OR 7.72 (95%CI: 1.20-49.79), P = 0.0316]. Controlling for age and sex and comparing HCM patients with a community-based SARS-CoV-2 cohort, the presence of HCM was associated with a borderline significant increased risk of mortality OR 1.70 (95%CI: 0.98-2.91, P = 0.0600). CONCLUSIONS Over one-fourth of HCM patients infected with SARS-Cov-2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality.engVoRhttp://creativecommons.org/licenses/by-sa/4.0/COVID-19Cardiomyopathy, HypertrophicVentricular Dysfunction, LeftAtrial FibrillationHumansMaleAdultMiddle AgedAgedFemaleSARS-CoV-2RegistriesAtribución-CompartirIgual 4.0 Internacional3625528194218910.1002/ehf2.139642055-5822ESC heart failureopen access